Analysis of the Cochrane Review: Omega-3 Fatty Acids for the Treatment of Dementia. Cochrane Database Syst Rev. 2016;4:CD009002.

Authors

  • David Cordeiro Sousa Serviço de Oftalmologia. Hospital de Santa Maria. Centro Hospitalar de Lisboa Norte. Lisboa. Portugal. Centro de Estudos das Ciências da Visão. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
  • Guilherme Ferreira Dos SANTOS Departamento de Medicina Física e Reabilitação. Hospital de Curry Cabral. Centro Hospitalar de Lisboa Central. Lisboa. Portugal. Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
  • João Costa Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Centro Colaborador Português da Rede Cochrane Iberoamericana. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.
  • António Vaz-Carneiro Centro de Estudos de Medicina Baseada na Evidência. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Instituto de Medicina Preventiva e Saúde Pública. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal. Centro Colaborador Português da Rede Cochrane Iberoamericana. Faculdade de Medicina. Universidade de Lisboa. Lisboa. Portugal.

DOI:

https://doi.org/10.20344/amp.9743

Keywords:

Omega-3 Fatty Acids, Dementia, Randomized Controlled Trials, Systematic Review

Abstract

Dietary supplementation with omega-3 polyunsaturated fatty acids from fish and plant sources is commonly prescribed as a nonfarmacological alternative to improve brain functions and slow down the progression of dementia. This use is mostly based on findings of preclinical studies which established the role of omega-3 polyunsaturated fatty acids in the development and integrity of the brain, as well as epidemiological research that found evidence of malnutrition in patients with dementia. This Cochrane systematic review included three randomized, placebo-controlled trials at low risk of bias, in which omega-3 polyunsaturated fatty acids were administered to people with mild to moderate Alzheimer’s disease in the form of supplements. Of the main results of this systematic review we highlight the lack of convincing evidence for the efficacy of omega-3 polyunsaturated fatty acids supplementation in the treatment of patients with Alzheimer’s disease, as well as the low frequency of reported adverse events, with a comparable overall frequency between omega-3 polyunsaturated fatty acids and the placebo groups. The effects on other populations with dementia remain unclear. This paper aims to summarize and discuss the main results and conclusions of this systematic review, as well as its implications for the daily clinical practice.

Downloads

Download data is not yet available.

Published

2017-10-31

How to Cite

1.
Sousa DC, SANTOS GFD, Costa J, Vaz-Carneiro A. Analysis of the Cochrane Review: Omega-3 Fatty Acids for the Treatment of Dementia. Cochrane Database Syst Rev. 2016;4:CD009002. Acta Med Port [Internet]. 2017 Oct. 31 [cited 2024 Mar. 1];30(10):671-4. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/9743

Issue

Section

Cochrane Corner